高级检索
    肖招兰, 谭建明. ATG及巴利昔单抗对心脏死亡器官捐献供者肾移植术后DGF的影响分析[J]. 徐州医科大学学报, 2018, 38(10): 664-667.
    引用本文: 肖招兰, 谭建明. ATG及巴利昔单抗对心脏死亡器官捐献供者肾移植术后DGF的影响分析[J]. 徐州医科大学学报, 2018, 38(10): 664-667.
    shu
    Effect of ATG and Bromiximab on DGF in Kidney Transplantation after Cardiac Death Organ Donors[J]. Journal of Xuzhou Medical University, 2018, 38(10): 664-667.
    Citation: Effect of ATG and Bromiximab on DGF in Kidney Transplantation after Cardiac Death Organ Donors[J]. Journal of Xuzhou Medical University, 2018, 38(10): 664-667.
    shu

    ATG及巴利昔单抗对心脏死亡器官捐献供者肾移植术后DGF的影响分析

    Effect of ATG and Bromiximab on DGF in Kidney Transplantation after Cardiac Death Organ Donors

      摘要
    • 摘要: 目的：研究抗胸腺细胞球蛋白(ATG)和巴利昔单抗在心脏死亡器官捐献(DCD)供者肾移植术后的临床疗效及安全性。方法：选取我院接受的供者56例和112个肾脏，同时选取2014年10月到2017年2月间行肾移植术患者112例作为研究对象，采用随机数字法将其分为对照组和观察组，每组各56例。对照组患者术后接受巴利昔单抗免疫治疗，观察组患者接受ATG免疫治疗。比较两组患者术后移植物功能恢复延迟(DGF)、急性排斥反应及其他并发症发生率，同时比较术后1年的移植物存活率和患者生存率。结果：观察组的DGF发生率明显低于对照组(P)，观察组的住院感染和肝功能受损发生率均明显低于对照组(P<0.05)，急性排斥反应出院后感染、血小板减少、贫血、白细胞减少及新发糖尿病等并发症发生率比较均无明显差异(P>0.05)两组患者术后1年的生存率和移植物存活率比较均无明显差异(P>0.05)结论：ATG能明显降低心DCD供者肾移植术后DGF发生率，促进患者术后恢复，尤其对高危患者效果更为显著，值得在临床推广。

       

      Abstract: Objective:To study the clinical efficacy and safety of anti-thymocyte globulin (ATG) and basiliximab in donor heart organ death (DCD) donor kidney transplantation.Methods:We selected 56 cases of DCD donors and 112 kidneys,and 112 patients with renal transplantation from October 2014 to February 2017 were selected as subjects,randomly divided into control group and observation group ,each group of 56 cases.Patients in the control group received postoperative baclitaxel immunotherapy, and the observation group received ATG immunotherapy.compared two groups after surgery of the graft recovery rate (DGF), acute rejection and other complications,and compared the graft survival rate and patient survival rate in one year after operation.Results:The incidence of DGF and the time of hospitalization were significantly lower in the observation group than in the control group (P<0.05). The incidence of hospital infection and impaired liver function in the observation group was significantly lower than that in the control group (P<0.05) The incidence of DGF was significantly lower in the patients than in the control group (P<0.05). There was no significant difference in the incidence of complications such as acute rejection, post-discharge infection, thrombocytopenia, anemia, leukopenia and newly diagnosed diabetes mellitus(P>0.05). There was no significant difference in the survival rate and graft survival rate between the two groups (P>0.05).Conclusion:ATG can significantly reduce the incidence of DGF after cardiac transplantation in patients with heart DCD, and promote the recovery of patients after operation, especially for high-risk patients, which is worthy of clinical promotion

       

      • HTML全文
      • 参考文献(0)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回